Barrett's esophagus (BE) is a metaplastic disorder where dysplastic and early cancerous changes are invisible to the naked eye and where the practice of blind biopsy is hampered by large sampling errors. Multi-photon microscopy (MPM) has emerged as an alternative solution for fast and label-free diagnostic capability for identifying the histological features with sub-micron accuracy. We developed a compact, inexpensive MPM system by using a handheld mode-locked fiber laser operating at 1560nm to study mucosal biopsies of BE. The combination of back-scattered THG, back-reflected forward THG and SHG signals generate images of cell nuclei and collagen, leading to label-free diagnosis in Barrett's.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4722899PMC
http://dx.doi.org/10.1364/BOE.7.000148DOI Listing

Publication Analysis

Top Keywords

barrett's esophagus
8
label-free multi-photon
4
multi-photon imaging
4
imaging dysplasia
4
dysplasia barrett's
4
esophagus barrett's
4
esophagus metaplastic
4
metaplastic disorder
4
disorder dysplastic
4
dysplastic early
4

Similar Publications

Background And Aims: We sought to develop a minimally-invasive, robust, accessible nonendoscopic strategy to diagnose Barrett's esophagus (BE), esophageal adenocarcinoma (EAC), and its immediate precursor lesion, high-grade dysplasia (HGD) based on methylated DNA biomarkers applied to a retrievable sponge-capsule device in a cohort representative of the BE population (i.e., mostly short-segment, non-dysplastic BE, NDBE).

View Article and Find Full Text PDF

Photodynamic therapy (PDT) is a treatment modality clinically approved for several oncologic indications, including esophageal and endobronchial cancers, precancerous conditions including Barrett's esophagus and actinic keratosis, and benign conditions like age-related macular degeneration. While it is currently clinically underused, PDT is an area of significant research interest. Because PDT relies on the absorption of light energy by intrinsic or administered absorbers, the dosimetric quantity of interest is the absorbed energy per unit mass of tissue, proportional to the fluence rate of light in tissue.

View Article and Find Full Text PDF

Background: In the UK's National Health Service (NHS), there is specific psychosocial care offered to people with genetic cancer risk conditions but not morphological cancer risk conditions. As researchers develop new ways to diagnose morphological risk conditions, including precancers and in situ cancers, it is important to consider the psychosocial care that those diagnosed might require.

Objectives: This study compares the National Institute for Health and Care Excellence's guidelines for BRCA1/2, which are genetic risk conditions, and Barrett's oesophagus (BO), a morphological risk condition.

View Article and Find Full Text PDF

Background: Acid reflux is a common presentation in primary care leading to a high volume of referrals to endoscopy that are often normal.

Aims: To determine whether a non-endoscopic capsule sponge biomarker test could triage patients with low-risk reflux symptoms, reduce endoscopy waiting lists and identify Barrett's oesophagus in a real-world setting.

Methods: Patients with reflux symptoms on NHS endoscopy waiting lists who were offered a capsule sponge (test group) between February 2021 and August 2022 were included in this national multicentre prospective cohort study and compared with eligible patients on the standard endoscopy pathway (counterfactual group).

View Article and Find Full Text PDF

Histological features indicate the risk of progression of patients with Barrett's esophagus.

Pathol Res Pract

January 2025

Department of Pathology and Laboratory Medicine, Penn State Health Hershey Medical Center, Penn State College of Medicine, Hershey, PA 17033, United States. Electronic address:

Our understanding of predictors of progression in Barrett's esophagus (BE) remains incomplete. To address this gap, we evaluated histological features and biomarkers that could predict dysplastic/neoplastic progression in patients with BE. We conducted a retrospective study to identify eligible BE patients and classified the cases into two groups: cases with BE progression (n = 10; progressing to high-grade dysplasia or carcinoma within five years of initial diagnosis) and cases without BE progression (n = 52; without progression to high-grade dysplasia or carcinoma within five years).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!